Humana Inc (HUM) stock
HUMNYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 10/3051% above fair value
$450.00+6.32 (+1.42%)
Close on Nov 13, 2026Market cap $54.04BP/E 43.6Yield 0.79%
Humana EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Humana's EPS for the twelve months ending Sep 30, 2026 was $10.31, down 3.6% year over year. For fiscal 2025 it was $9.84, down 1.4% from the year before. Over ten years it grew 1.5% a year on average. The highest annual figure on record is $25.31 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.84 | -1.4% |
| FY2024 | Dec 31, 2024 | $9.98 | -50.1% |
| FY2023 | Dec 31, 2023 | $20.00 | -9.4% |
| FY2022 | Dec 31, 2022 | $22.08 | -2.6% |
| FY2021 | Dec 31, 2021 | $22.67 | -10.4% |
| FY2020 | Dec 31, 2020 | $25.31 | +25.9% |
| FY2019 | Dec 31, 2019 | $20.10 | +65.3% |
| FY2018 | Dec 31, 2018 | $12.16 | -27.7% |
| FY2017 | Dec 31, 2017 | $16.81 | +313.0% |
| FY2016 | Dec 31, 2016 | $4.07 | -51.8% |
| FY2015 | Dec 31, 2015 | $8.44 | +14.7% |
| FY2014 | Dec 31, 2014 | $7.36 | -4.8% |
| FY2013 | Dec 31, 2013 | $7.73 | +3.5% |
| FY2012 | Dec 31, 2012 | $7.47 | -11.7% |
| FY2011 | Dec 31, 2011 | $8.46 | +30.8% |
| FY2010 | Dec 31, 2010 | $6.47 | +5.2% |
| FY2009 | Dec 31, 2009 | $6.15 | +60.6% |
| FY2008 | Dec 31, 2008 | $3.83 | -22.0% |
| FY2007 | Dec 31, 2007 | $4.91 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.33 | -17.9% |
| Q2 FY2026 | Jun 30, 2026 | $5.73 | +27.1% |
| Q1 FY2026 | Mar 31, 2026 | $9.83 | -4.6% |
| Q4 FY2025 | Dec 31, 2025 | -$6.58 | – |
| Q3 FY2025 | Sep 30, 2025 | $1.62 | -59.3% |
| Q2 FY2025 | Jun 30, 2025 | $4.51 | -19.8% |
| Q1 FY2025 | Mar 31, 2025 | $10.30 | +68.6% |
| Q4 FY2024 | Dec 31, 2024 | -$5.74 | – |
| Q3 FY2024 | Sep 30, 2024 | $3.98 | -40.7% |
| Q2 FY2024 | Jun 30, 2024 | $5.62 | -26.6% |
| Q1 FY2024 | Mar 31, 2024 | $6.11 | -38.1% |
| Q4 FY2023 | Dec 31, 2023 | -$4.39 | – |
| Q3 FY2023 | Sep 30, 2023 | $6.71 | -28.5% |
| Q2 FY2023 | Jun 30, 2023 | $7.66 | +39.8% |
| Q1 FY2023 | Mar 31, 2023 | $9.87 | +35.4% |
| Q4 FY2022 | Dec 31, 2022 | -$0.12 | – |
| Q3 FY2022 | Sep 30, 2022 | $9.39 | -20.7% |
| Q2 FY2022 | Jun 30, 2022 | $5.48 | +20.4% |
| Q1 FY2022 | Mar 31, 2022 | $7.29 | +14.1% |
| Q4 FY2021 | Dec 31, 2021 | -$0.11 | – |
| Q3 FY2021 | Sep 30, 2021 | $11.84 | +17.8% |
| Q2 FY2021 | Jun 30, 2021 | $4.55 | -66.9% |
| Q1 FY2021 | Mar 31, 2021 | $6.39 | +79.5% |
| Q4 FY2020 | Dec 31, 2020 | -$2.06 | -153.6% |
| Q3 FY2020 | Sep 30, 2020 | $10.05 | +95.5% |
| Q2 FY2020 | Jun 30, 2020 | $13.75 | +98.1% |
| Q1 FY2020 | Mar 31, 2020 | $3.56 | -14.4% |
| Q4 FY2019 | Dec 31, 2019 | $3.84 | +48.8% |
| Q3 FY2019 | Sep 30, 2019 | $5.14 | +10.5% |
| Q2 FY2019 | Jun 30, 2019 | $6.94 | +399.3% |
| Q1 FY2019 | Mar 31, 2019 | $4.16 | +17.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.58 | +100.0% |
| Q3 FY2018 | Sep 30, 2018 | $4.65 | +35.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.39 | -68.8% |
| Q1 FY2018 | Mar 31, 2018 | $3.53 | -52.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.29 | – |
| Q3 FY2017 | Sep 30, 2017 | $3.44 | – |
| Q2 FY2017 | Jun 30, 2017 | $4.46 | – |
| Q1 FY2017 | Mar 31, 2017 | $7.49 | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.68 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?